Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Is in good health
- Is confirmed human immunodeficiency virus (HIV)-uninfected
- Is at low risk of HIV infection
- For males, uses contraception in accordance with local regulations regarding contraception use for those participating in clinical trials
- For females, is not pregnant or breastfeeding and one of the following applies:
- Is not a participant of childbearing potential (POCBP)
- Is a POCBP and uses an acceptable contraception method or is abstinent
Exclusion Criteria:
- Has an active diagnosis of hepatitis (B or C) due to any cause
- Has a history of malignancy ≤5 years before signing informed consent
- Has a history or current evidence of any condition that might confound study results or interfere with study participation
- Has a history of keloid in upper arm or presence of tattoo, scar, or other physical finding that could interfere with implant placement (the contralateral arm may be used if the findings are limited to 1 arm)
- Is taking or is expected to take immunosuppressants during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Islatravir 47 mg
Participants receive an ISL 47 mg implant for approximately 52 weeks.
A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
|
ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
Other Names:
|
|
Experimental: Islatravir 52 mg
Participants receive an ISL 52 mg implant for approximately 52 weeks.
A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
|
ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
Other Names:
|
|
Experimental: Islatravir 57 mg
Participants receive an ISL 57 mg implant for approximately 52 weeks.
A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
|
ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
Other Names:
|
|
Placebo Comparator: Placebo
Participants receive a placebo implant for approximately 52 weeks.
A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
|
Placebo implantable rod placed subdermally on the upper arm.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants with ≥1 adverse events (AEs)
Time Frame: Up to 60 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to 60 weeks
|
|
Percentage of participants withdrawing from study treatment due to adverse event (AE)
Time Frame: Up to 52 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to 52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma concentration of islatravir (ISL) 12 weeks after placement of an ISL-eluting implant (ISL C12weeks)
Time Frame: Week 12
|
Plasma ISL C12weeks will be determined.
|
Week 12
|
|
Plasma concentration of islatravir (ISL) 52 weeks after placement of an ISL-eluting implant (ISL C52weeks)
Time Frame: Week 52
|
Plasma ISL C52weeks will be determined.
|
Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Retroviral Agents
- Islatravir
Other Study ID Numbers
Other Study ID Numbers
- 8591-043
- 2021-003414-39 (EudraCT Number)
- MK-8591-043 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.